Icotinib
EGFR L858R
Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the EGFR L858R cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
Carboplatin Blueprint Medicines Corporation | Phase 1 | CC |
Osimertinib Blueprint Medicines Corporation | Phase 1 | CC |
Same molecule, other indications
Icotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →